These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25300346)

  • 1. PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.
    Zhang X; Park JS; Park KH; Kim KH; Jung M; Chung HC; Rha SY; Kim HS
    Oncology; 2015; 88(2):76-85. PubMed ID: 25300346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis.
    Wang Y; Liu Y; Du Y; Yin W; Lu J
    Curr Med Res Opin; 2013 Jun; 29(6):633-42. PubMed ID: 23574264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.
    Deguchi Y; Okabe H; Oshima N; Hisamori S; Minamiguchi S; Muto M; Sakai Y
    Gastric Cancer; 2017 May; 20(3):416-427. PubMed ID: 27517839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
    Sueta A; Yamamoto Y; Yamamoto-Ibusuki M; Hayashi M; Takeshita T; Yamamoto S; Iwase H
    PLoS One; 2014; 9(12):e116054. PubMed ID: 25542038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
    Nuciforo PG; Aura C; Holmes E; Prudkin L; Jimenez J; Martinez P; Ameels H; de la Peña L; Ellis C; Eidtmann H; Piccart-Gebhart MJ; Scaltriti M; Baselga J
    Ann Oncol; 2015 Jul; 26(7):1494-500. PubMed ID: 25851628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
    Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone.
    Xu B; Guan Z; Shen Z; Tong Z; Jiang Z; Yang J; DeSilvio M; Russo M; Leigh M; Ellis C
    Breast Cancer Res; 2014 Jul; 16(4):405. PubMed ID: 25056500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
    Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
    Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
    Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
    Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
    Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
    J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 expression and PI3K-Akt pathway alterations in gastric cancer.
    Sukawa Y; Yamamoto H; Nosho K; Ito M; Igarashi H; Naito T; Mitsuhashi K; Matsunaga Y; Takahashi T; Mikami M; Adachi Y; Suzuki H; Shinomura Y
    Digestion; 2014; 89(1):12-7. PubMed ID: 24458107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma.
    Yokoyama D; Hisamori S; Deguchi Y; Nishigori T; Okabe H; Kanaya S; Manaka D; Kadokawa Y; Hata H; Minamiguchi S; Tsunoda S; Obama K; Sakai Y
    Sci Rep; 2021 Apr; 11(1):9013. PubMed ID: 33907203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas.
    Im SA; Lee KE; Nam E; Kim DY; Lee JH; Han HS; Seoh JY; Park HY; Cho MS; Han WS; Lee SN
    Tumori; 2005; 91(6):513-21. PubMed ID: 16457151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
    Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
    J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
    Zhang C; Xu B; Liu P
    Tumour Biol; 2016 Nov; 37(11):14831-14839. PubMed ID: 27639383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.
    Mukohara T
    Cancer Sci; 2011 Jan; 102(1):1-8. PubMed ID: 20825420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
    Berns K; Horlings HM; Hennessy BT; Madiredjo M; Hijmans EM; Beelen K; Linn SC; Gonzalez-Angulo AM; Stemke-Hale K; Hauptmann M; Beijersbergen RL; Mills GB; van de Vijver MJ; Bernards R
    Cancer Cell; 2007 Oct; 12(4):395-402. PubMed ID: 17936563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
    Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
    BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: meta-analysis, co-occurrence and ethnic variation.
    Chong ML; Loh M; Thakkar B; Pang B; Iacopetta B; Soong R
    Int J Cancer; 2014 Mar; 134(5):1232-8. PubMed ID: 23960014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.